Paper36044100
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Pedrosa MR and 8 others. Curr Atheroscler Rep, 2022. Cited by 52 papers, by iCite.
Cite this record
ConductScience Library. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Papers, record 36044100. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36044100
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cardiovascular Diseases | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Clinical Trials as Topic | |
| Glucagon-Like Peptide 1 | |
| Glucagon-Like Peptide-1 Receptor | |
| Humans | |
| Hypoglycemic Agents | |
| Liraglutide | |
| Obesity | |
| Weight Loss | |
| Glucagon-Like Peptide-1 Receptor Agonists |
Source PubMed
References118
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34137731 | How glucagon-like peptide 1 receptor agonists work. | Endocr Connect | 2021 | https://conductscience.org/library/papers/34137731 | PubMed |
| 2 | 28950422 | Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. | Diabetes Obes Metab | 2018 | https://conductscience.org/library/papers/28950422 | PubMed |
| 3 | 22990267 | Cardiovascular risk assessment in the development of new drugs for obesity. | JAMA | 2012 | https://conductscience.org/library/papers/22990267 | PubMed |
| 4 | 31166153 | Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. | J Am Heart Assoc | 2019 | https://conductscience.org/library/papers/31166153 | PubMed |
| 5 | 32511781 | The pivotal relation between glucagon-like peptides, NFκB and inflammatory bowel disease. | Clin Exp Pharmacol Physiol | 2020 | https://conductscience.org/library/papers/32511781 | PubMed |
| 6 | 33984333 | Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis. | J Pediatr | 2021 | https://conductscience.org/library/papers/33984333 | PubMed |
| 7 | 34268675 | Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs). | Diabetes Ther | 2021 | https://conductscience.org/library/papers/34268675 | PubMed |
| 8 | 34235727 | Actions of glucagon-like peptide-1 receptor ligands in the gut. | Br J Pharmacol | 2022 | https://conductscience.org/library/papers/34235727 | PubMed |
| 9 | 34859263 | Association between weight change and incidence of cardiovascular disease events and mortality among adults with type 2 diabetes: a systematic review of observational studies and behavioural intervention trials. | Diabetologia | 2022 | https://conductscience.org/library/papers/34859263 | PubMed |
| 10 | 35131037 | Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. | Lancet Diabetes Endocrinol | 2022 | https://conductscience.org/library/papers/35131037 | PubMed |
| 11 | 34170647 | Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34170647 | PubMed |
| 12 | 20457158 | Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. | Gastroenterology | 2010 | https://conductscience.org/library/papers/20457158 | PubMed |
| 13 | 1326760 | Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. | Proc Natl Acad Sci U S A | 1992 | https://conductscience.org/library/papers/1326760 | PubMed |
| 14 | 28349386 | Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment. | Clin Pharmacokinet | 2017 | https://conductscience.org/library/papers/28349386 | PubMed |
| 15 | 23812094 | Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. | Int J Obes (Lond) | 2013 | https://conductscience.org/library/papers/23812094 | PubMed |
| 16 | 30067154 | Mechanisms of Insulin Action and Insulin Resistance. | Physiol Rev | 2018 | https://conductscience.org/library/papers/30067154 | PubMed |
| 17 | 33068776 | GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. | Mol Metab | 2021 | https://conductscience.org/library/papers/33068776 | PubMed |
| 18 | 33462955 | The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. | Diabetes Obes Metab | 2020 | https://conductscience.org/library/papers/33462955 | PubMed |
| 19 | 30473097 | LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. | Mol Metab | 2018 | https://conductscience.org/library/papers/30473097 | PubMed |
| 20 | 21295846 | National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. | Lancet | 2011 | https://conductscience.org/library/papers/21295846 | PubMed |
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42761830 | Liraglutide and renal mitochondrial homeostasis: targeting the "metabolism-inflammation-lithogenesis" axis in metabolic syndrome. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42761830 | PubMed |
| 42583965 | Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection. | Indian J Pharmacol | 2026 | https://conductscience.org/library/papers/42583965 | PubMed |
| 41965670 | Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists- preliminary study. | J Transl Med | 2026 | https://conductscience.org/library/papers/41965670 | PubMed |
| 41367404 | GLP-1 agonists and exercise: the future of lifestyle prioritization. | Front Clin Diabetes Healthc | 2025 | https://conductscience.org/library/papers/41367404 | PubMed |
| 41140718 | Goal Integration of Diabetes Self-Management Education and Psychosocial Support With Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes and Obesity. | Clin Diabetes | 2025 | https://conductscience.org/library/papers/41140718 | PubMed |
| 41001395 | GLP-1 receptor agonist increase retained gastric contents on EGD and same-day colonoscopy reduces this risk. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41001395 | PubMed |
| 40765557 | Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models. | Int J Med Sci | 2025 | https://conductscience.org/library/papers/40765557 | PubMed |
| 40732345 | Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40732345 | PubMed |
| 40607222 | Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/40607222 | PubMed |
| 40301134 | GLP-1R agonists: recent advances, current gaps, and future challenges. | Mol Divers | 2026 | https://conductscience.org/library/papers/40301134 | PubMed |
| 40149944 | Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. | Biomolecules | 2025 | https://conductscience.org/library/papers/40149944 | PubMed |
| 40143174 | Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40143174 | PubMed |
| 40062102 | Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes. | Cureus | 2025 | https://conductscience.org/library/papers/40062102 | PubMed |
| 39990178 | Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis. | Diabetes Metab Syndr Obes | 2025 | https://conductscience.org/library/papers/39990178 | PubMed |
| 39910018 | The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysis. | Obes Surg | 2025 | https://conductscience.org/library/papers/39910018 | PubMed |
| 39858999 | The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39858999 | PubMed |
| 39762910 | Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. | Reprod Biol Endocrinol | 2025 | https://conductscience.org/library/papers/39762910 | PubMed |
| 39283562 | Mechanisms of ferroptosis and glucagon-like peptide-1 receptor agonist in post-percutaneous coronary intervention restenosis. | Mol Cell Biochem | 2025 | https://conductscience.org/library/papers/39283562 | PubMed |
| 39139038 | Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future. | Med Res Rev | 2025 | https://conductscience.org/library/papers/39139038 | PubMed |
| 39099671 | Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/39099671 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GIP | 2695 | PubTator's text mining | https://conductscience.org/library/genes/2695 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36044100
GET https://conductscience.org/api/papers/v1/36044100/references?page=2